2m 2m 2m 2m 2m 2m 2m
Solventum (SOLV)
NYSE
$74.00+$0.44 (+0.59%)
Price as of Jun 23, 2026 6:30 PM EDT- $12.7BMarket Cap
- 0.42%1-Year Change
- Medical Instruments & SuppliesIndustry
Solventum (SOLV)
$74.00+$0.44 (+0.59%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 6.3B -23.08% | 8.3B N/A | |
Cost of Revenue | 3.4B -18.96% | 4.2B N/A | |
Gross Profit | 4.5B -3.09% | 4.6B N/A | |
Sales and Marketing Expense | 3.1B +10.71% | 2.8B N/A | |
Research and Development Expense | -739.0M -4.65% | -775.0M N/A | |
Depreciation and Amortization Expense | 489.0M -11.89% | 555.0M N/A | |
Total Operating Expenses | 3.4B -18.96% | 4.2B N/A | |
Operating Profit | 2.2B +110.52% | 1.0B N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -347.0M -5.45% | -367.0M N/A | |
Interest Income and Expense and Net | -347.0M -5.45% | -367.0M N/A | |
Total Nonoperating Income and Expense | -39.0M -39.06% | -64.0M N/A | |
Income before Taxes | 1.7B +183.14% | 605.0M N/A | |
Income Taxes | 157.0M +23.62% | 127.0M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | 1.6B +224.84% | 479.0M N/A | |
Net Income from Continuing Operations Applicable to Common | 1.7B +183.14% | 605.0M N/A | |
Basic EPS and Net Income | 8.94 +222.74% | 2.77 N/A | |
Diluted EPS and Net Income | 8.88 +221.74% | 2.76 N/A | |
Basic Weighted Average Shares | 174.1M +0.52% | 173.2M N/A | |
Diluted Weighted Average Shares | 175.3M +0.92% | 173.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 878.0M +15.22% | 762.0M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 878.0M +15.22% | 762.0M N/A | |
Total Current Assets | 3.9B +18.78% | 3.2B N/A | |
Accumulated Depreciation | 1.9B -6.09% | 2.0B N/A | |
Property and Plant and Equipment and Net | 1.3B -18.25% | 1.6B N/A | |
Total Long-Term Assets | 814.0M +22.41% | 665.0M N/A | |
Total Assets | 14.3B -1.13% | 14.5B N/A | |
Income Taxes Payable | 164.0M -27.11% | 225.0M N/A | |
Total Short-Term Debt | 0 -100.00% | 200.0M N/A | |
Total Current Liabilities | 3.1B +16.02% | 2.7B N/A | |
Total Long-Term Debt | 5.0B -35.53% | 7.8B N/A | |
Total Long-Term Liabilities | 547.0M +33.41% | 410.0M N/A | |
Total Liabilities | 9.2B -19.59% | 11.5B N/A | |
Retained Earnings | 1.8B +642.56% | 242.0M N/A | |
Total Stockholders Equity | 5.0B +70.63% | 3.0B N/A | |
Total Shares Outstanding | 173.5M +0.41% | 172.8M N/A | |
Cash Flow | |||
Cash from Operating Activities | 369.0M -68.86% | 1.2B N/A | |
Capital Expenditures | 379.0M -0.26% | 380.0M N/A | |
Cash from Investing Activities | 2.8B +836.05% | -380.0M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | -3.1B +1,173.75% | -240.0M N/A | |
Financials Ratio | |||
Gross Margin | 46.42% N/A | N/A N/A | |
Operating Margin | 34.35% N/A | N/A N/A | |
Return on Assets | 10.82% N/A | N/A N/A | |
Return on Equity | 38.86% N/A | N/A N/A | |
Revenue Growth | -23.08% N/A | N/A N/A | |
Current Ratio | 1.23 N/A | N/A N/A | |
Cash Ratio | 0.28 N/A | N/A N/A | |
Debt-to-Equity Ratio | 1.00 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.35 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow